MXPA04003215A - Derivados de triazapina como agentes neurotroficos. - Google Patents

Derivados de triazapina como agentes neurotroficos.

Info

Publication number
MXPA04003215A
MXPA04003215A MXPA04003215A MXPA04003215A MXPA04003215A MX PA04003215 A MXPA04003215 A MX PA04003215A MX PA04003215 A MXPA04003215 A MX PA04003215A MX PA04003215 A MXPA04003215 A MX PA04003215A MX PA04003215 A MXPA04003215 A MX PA04003215A
Authority
MX
Mexico
Prior art keywords
neurotrophic agents
disease
triazepine
derivatives
triazepine derivatives
Prior art date
Application number
MXPA04003215A
Other languages
English (en)
Spanish (es)
Inventor
Shawn P Walsh
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MXPA04003215A publication Critical patent/MXPA04003215A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MXPA04003215A 2001-10-04 2002-10-04 Derivados de triazapina como agentes neurotroficos. MXPA04003215A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32692701P 2001-10-04 2001-10-04
PCT/US2002/031679 WO2003028734A1 (en) 2001-10-04 2002-10-04 Triazepine derivatives as neurotrophic agents

Publications (1)

Publication Number Publication Date
MXPA04003215A true MXPA04003215A (es) 2005-01-25

Family

ID=23274355

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003215A MXPA04003215A (es) 2001-10-04 2002-10-04 Derivados de triazapina como agentes neurotroficos.

Country Status (9)

Country Link
EP (1) EP1446127B1 (enExample)
JP (1) JP2005504823A (enExample)
AT (1) ATE347893T1 (enExample)
AU (1) AU2002334837B2 (enExample)
CA (1) CA2462643A1 (enExample)
DE (1) DE60216807T2 (enExample)
ES (1) ES2278078T3 (enExample)
MX (1) MXPA04003215A (enExample)
WO (1) WO2003028734A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1240691C (zh) * 2001-12-06 2006-02-08 中国人民解放军军事医学科学院毒物药物研究所 取代五元氮杂环类化合物及其预防和治疗神经退行性疾病的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
FR1511147A (fr) * 1966-12-16 1968-01-26 Soc Ind Fab Antibiotiques Sifa Nouveaux dérivés de la 11 h-dibenzotriazépine-1, 2, 5 et leurs sels, et procédéde préparation

Also Published As

Publication number Publication date
EP1446127B1 (en) 2006-12-13
CA2462643A1 (en) 2003-04-10
EP1446127A1 (en) 2004-08-18
ATE347893T1 (de) 2007-01-15
DE60216807T2 (de) 2007-10-04
ES2278078T3 (es) 2007-08-01
JP2005504823A (ja) 2005-02-17
AU2002334837B2 (en) 2007-03-15
DE60216807D1 (de) 2007-01-25
WO2003028734A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
MXPA05002420A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos.
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
MXPA04005376A (es) Composiciones farmaceuticas y sus usos.
BG105588A (en) Anthranilic acide amides and the use thereof as medicaments
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MXPA04005456A (es) Derivados de acetileno que tienen actividad antagonistica de mglur5.
MXPA04002583A (es) Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1).
GB0225475D0 (en) Therapeutic agents
TWI265928B (en) A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw
IL175762A0 (en) Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
TW200502221A (en) Novel lactams and uses thereof
CA2534532A1 (en) Compounds for the treatment of neurodegenerative disorders
CA2498291A1 (en) Diazabicyclic compounds useful in the treatment of cns and other disorders
TW200509933A (en) Therapeutic agents
PL346143A1 (en) Tan-1057 derivatives
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
CY1107362T1 (el) Παραγωγα ιμιδαζολυλιου χρησιμα ως συνδετες υποδοχεων ισταμινης h3
DE602004019500D1 (en) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
ATE294794T1 (de) N-heterocyclylhydrazide als neurotrophe mittel
MXPA04003215A (es) Derivados de triazapina como agentes neurotroficos.
EP1958939A3 (en) Pyrazole-amine compounds for the treatment of neurodegenerative disorders
ZA200700945B (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
BR0113814A (pt) Amidas de ácido fenilciclohexanocarboxìlico e sua aplicação

Legal Events

Date Code Title Description
FG Grant or registration